Apple Watch's Redesigned ECG Doesn't Infringe AliveCor Patents, Rules US Customs (UPDATED)
Portfolio Pulse from Benzinga Neuro
The U.S. Customs and Border Protection has ruled that the redesigned ECG in the Apple Watch does not infringe on AliveCor's patents, allowing Apple to import these models without additional costs. This decision is a setback for AliveCor in its ongoing legal battles against Apple.
July 16, 2024 | 6:25 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The U.S. Customs and Border Protection has ruled that the redesigned ECG in the Apple Watch does not infringe on AliveCor's patents. This allows Apple to import these models without paying a $2 bond per unit, marking a significant legal win for Apple.
The ruling allows Apple to continue importing and selling its redesigned Apple Watch models without additional costs, which is a positive development for the company. This decision also mitigates potential legal and financial risks associated with the patent dispute.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100